504
Participants
Start Date
May 1, 2012
Primary Completion Date
April 29, 2021
Study Completion Date
June 30, 2021
POL-103A
POL-103A is administered intradermally, divided into 4 injections (0.2 mL each injection) into the volar surface of forearms and into the anterior upper thighs
POL-103A without API
Placebo is administered intradermally, divided into 4 injections (0.2 mL each injection) into the volar surface of forearms and into the anterior upper thighs
Mount Sinai School of Medicine, New York
Thomas Jefferson Medical Oncology, Philadelphia
McGlinn Cancer Institute, Reading Hospital, West Reading
The Melanoma Center at the Washington Cancer Institute, Washington D.C.
Harry & Jeanette Weinberg Cancer Institute @ Franklin Square, Baltimore
Inova Schar Cancer Center, Fairfax
University of Virginia Hospital, Charlottesville
Wake Forest University School of Medicine, Comprehensive Cancer Center, Winston-Salem
East Carolina University, Greenville
Ameriderm Research, Ormond Beach
GenesisCare USA of Florida, Jacksonville
Cancer Specialists of North Florida, Jacksonville
MD Anderson Cancer Center-Orlando, Orlando
Mount Sinai Medical Center, Miami Beach
University of Tennessee Medical Center, Knoxville
The West Clinic P.C. d/b/a West Cancer Center, Germantown
University of Louisville, Louisville
Baptist Health Lexington, Lexington
Central Kentucky Research Associates, Lexington
Hillcrest Hospital (Cleveland Clinic), Mayfield Heights
Independence Family Health Center (Cleveland Clinic), Independence
The Cleveland Clinic Foundation, Cleveland
Premier Health Partners Clinical Trials Research Alliance, Dayton
Investigative Clinical Research of Indiana, Indianapolis
Ascension Providence Hospital, Southfield
University of Iowa Hospitals and Clinics, Iowa City
University of Minnesota Masonic Cancer Institute, Minneapolis
Mayo Clinic Cancer Center, Mayo Clinic Rochester, Rochester
Advocate Medical Group, Niles
Southern Illinois University School of Medicine, Springfield
St. Louis University Hospital, St Louis
Washington University School of Medicine, St Louis
Center for Pharmaceutical Research, Kansas City
MediSearch Clinical Trials, Saint Joseph
University of Arkansas for Medical Sciences, Little Rock
Highlands Oncology Group, Fayetteville
Cancer Solutions, Dallas
Baylor Research Institute, Dallas
Center for Clinical Studies, Houston
Anschutz Cancer Pavilion, Aurora
Intermountain Medical Center, Murray
Ironwood Cancer and Research Centers, Chandler
University of Arizona Cancer Center, Tucson
The Angeles Clinic and Research Institute, Los Angeles
UCLA Hematology & Oncology Clinic, Los Angeles
Beverly Hills Cancer Center, Beverly Hills
City of Hope National Medical Center, Duarte
Ventura County Hematology Oncology Specialists, Oxnard
St. Mary's Hospital & Medical Center Department of Pathology, San Francisco
Sutter Cancer Center, Sacramento
Providence Portland Medical Center, Portland
Oregon Health and Science University, Portland
Bend Memorial Clinic, Bend
Virginia Mason Medical Center, Seattle
Multicare Institute for Research & Innovation, Tacoma
Norris Cotton Cancer Center / Dartmouth-Hitchcock Medical Center, Lebanon
John Theurer Cancer Center/ Hackensack Medical Center, Hackensack
Rutgers Cancer Institute of NJ, New Brunswick
The Huntsman Cancer Institute, University of Utah Health Care, Salt Lake City
BCCA Vancouver Island Cancer Centre, Victoria
Durham Regional Cancer Centre, Oshawa
Princess Margaret Hospital, Department of Medical Oncology, Toronto
CISSS de la Montérégie - Centre, Greenfield Park
Royal Victoria Hospital, Montreal
CHU de Quebec-L'Hotel-Dieu de Quebec, Québec
Lead Sponsor
Polynoma LLC
INDUSTRY